A Study to Learn About Abrocitinib in Adult Patients With Moderate to Severe Atopic Dermatitis.

Last updated: May 12, 2025
Sponsor: Pfizer
Overall Status: Active - Recruiting

Phase

N/A

Condition

Eczema (Atopic Dermatitis - Pediatric)

Rosacea

Skin Infections/disorders

Treatment

Abrocitinib

Clinical Study ID

NCT05689151
B7451096
ADAIR
  • Ages > 18
  • All Genders

Study Summary

The purpose of this study is to learn about the safety and effects of Abrocitinib in the real-life clinical setting given for the treatment of moderate to severe atopic dermatitis. Atopic dermatitis, or AD, is a long-lasting disease that causes inflammation, redness, and irritation of the skin.

This study is seeking participant who are older than 18 years with moderate-to-severe chronic AD. Participants must have no underlying medical conditions that prevent them from taking Abrocitinib.

All participants in this study will receive Abrocitinib as a tablet once daily. They can take Abrocitinib and use medicated topical treatment for AD at the same time.

We will examine the experiences of patients receiving the study medicine. This will help us determine if the study medicine is safe and helps in treating AD.

Participants will take part in this study for 24 months. During this time, they will visit the study clinic about 5 times (about 1 time every 4 to 6 months).

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Patients older than 18 years of age at inclusion.

  • Patients with clinical diagnosis of moderate-to-severe chronic atopic dermatitis (also referred to as atopic eczema) at inclusion according to the investigator andeligible for abrocitinib according to its marketing approval.

  • Patients that have been informed of the study procedures and have signed theconsent.

Exclusion

Exclusion Criteria:

  • Patients for whom abrocitinib is contraindicated.

  • Patients unable to follow and respect the study procedures and judged inapt torespond to the questions required for the study due to linguistical, psychological,social, or geographical reasons.

  • Patients not affiliated to the French social security system.

  • Patients deprived of liberty, under guardianship, or unable to provide oral consent.

  • Patients participating in a clinical study assessing a medicinal treatment (patientscan participate in registries and observatories).

Study Design

Total Participants: 183
Treatment Group(s): 1
Primary Treatment: Abrocitinib
Phase:
Study Start date:
March 09, 2023
Estimated Completion Date:
May 31, 2027

Connect with a study center

  • CHU Amiens-Picardie - Site Nord

    Amiens, Somme 80080
    France

    Active - Recruiting

  • CHU Besancon - Hopital Jean Minjoz

    Besancon, 25000
    France

    Active - Recruiting

  • Ch William Morey

    Chalon Sur Saone, 71100
    France

    Active - Recruiting

  • Chu Estaing

    Clermont Ferrand Cedex 1, 63003
    France

    Active - Recruiting

  • CHU Clermont Ferrand - Hopital Gabriel Montpied

    Clermont-Ferrand, 63000
    France

    Active - Recruiting

  • Chu Dijon

    Dijon, 21000
    France

    Active - Recruiting

  • Hopital Claude Huriez

    Lille, 59000
    France

    Active - Recruiting

  • Hopital Bichat

    Paris, 75018
    France

    Site Not Available

  • Hopital Saint Louis (APHP) - Service Hematologic Senior

    Paris CEDEX 10, 75475
    France

    Active - Recruiting

  • CHU Lyon Sud

    Pierre-Bénite, 69495
    France

    Active - Recruiting

  • Hopital Bégin

    Saint-Mande, 94160
    France

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.